Pepe G J, Jury H H, Hammond G L, Albrecht E D
Department of Physiology, Eastern Virginia Medical School, Norfolk, Virginia 23501, USA.
Endocrinology. 1996 Aug;137(8):3323-8. doi: 10.1210/endo.137.8.8754758.
The present study determined the roles of estrogen and cortisol in maternal and fetal corticosteroid-binding globulin (CBG) levels and fetal hepatic messenger RNA (mRNA) expression in the baboon. Samples of fetal liver, kidney, and brain were obtained from untreated control animals at early (day 60; n = 4), mid (day 100; n = 8), and late (day 165; n = 5) gestation (term = day 184). Maternal and umbilical blood samples were collected on day 100 from baboons in which betamethasone was administered sc to the mother (n = 6) on days 60-99 of gestation and on day 165 from animals (n = 4) in which the fetus was administered betamethasone on days 150-164 of gestation. Maternal serum cortisol concentrations were similar at mid (43 +/- 2 micrograms/dl) and late (42 +/- 3 micrograms/dl) gestation and decreased (P < 0.05) at midgestation (1 +/- 1 micrograms/dl) and term (31 +/- 4 micrograms/dl) after betamethasone treatment. Umbilical serum cortisol levels were also reduced (P < 0.05) at both mid (1 +/- 1 micrograms/dl) and late (14 +/- 5 micrograms/dl) gestation by betamethasone treatment. Fetal serum CBG levels in untreated animals were lower (P < 0.05) on day 165 (444 +/- 29 pmol/ml) than on day 100 (844 +/- 35 pmol/ml) and increased (P < 0.05) at midgestation (1098 +/- 64 pmol/ml), but not at term (551 +/- 24 pmol/ml), after betamethasone treatment. In contrast, maternal serum CBG levels (range, 528-770 pmol/ml) were not altered by gestational age or betamethasone. The human CBG complementary DNA hybridized to a single mRNA species of 1.8 kilobases in baboon fetal liver; however, CBG was not expressed in fetal kidney and was detectable in fetal brain and pancreas only by reverse transcription-PCR. In untreated baboon fetuses, the mRNA levels of hepatic CBG, expressed as a ratio of 18S RNA, progressively decreased (P < 0.05) in early (1.83 +/- 0.17), mid (0.97 +/- 0.12), and late (0.51 +/- 0.04) gestation. These results demonstrate that fetal hepatic CBG mRNA expression and serum CBG concentrations were elevated early in baboon gestation and exhibited a progressive decline during the course of advancing pregnancy. We suggest that the increased levels of fetal CBG in the early stages of gestation reflect stimulation of hepatic CBG synthesis by maternal cortisol, which we previously demonstrated to occur in the fetus as a result of preferential 11 beta-hydroxysteroid dehydrogenase-catalyzed glucocorticoid reduction across the placenta. The decline in fetal CBG may reflect the developmental increase in catabolism of cortisol to bioinactive cortisone in target tissues of the fetus such as the liver.
本研究确定了雌激素和皮质醇在狒狒母体及胎儿皮质类固醇结合球蛋白(CBG)水平以及胎儿肝脏信使核糖核酸(mRNA)表达中的作用。在妊娠早期(第60天;n = 4)、中期(第100天;n = 8)和晚期(第165天;n = 5)(足月为第184天)从未经处理的对照动物获取胎儿肝脏、肾脏和大脑样本。在妊娠第60 - 99天对母体皮下注射倍他米松的狒狒中,于第100天采集母体和脐血样本(n = 6);在妊娠第150 - 164天对胎儿注射倍他米松的动物中,于第165天采集样本(n = 4)。母体血清皮质醇浓度在妊娠中期(43±2微克/分升)和晚期(42±3微克/分升)相似,在倍他米松治疗后,妊娠中期(1±1微克/分升)和足月时(31±4微克/分升)降低(P < 0.05)。倍他米松治疗使脐血血清皮质醇水平在妊娠中期(1±1微克/分升)和晚期(14±5微克/分升)也降低(P < 0.05)。未经处理动物的胎儿血清CBG水平在第165天(444±29皮摩尔/毫升)低于第100天(844±35皮摩尔/毫升)(P < 0.05),在倍他米松治疗后,妊娠中期升高(P < 0.05)(1098±64皮摩尔/毫升),但足月时未升高(551±24皮摩尔/毫升)。相比之下,母体血清CBG水平(范围为528 - 770皮摩尔/毫升)不受胎龄或倍他米松影响。人CBG互补DNA与狒狒胎儿肝脏中一种1.8千碱基的单一mRNA种类杂交;然而,CBG在胎儿肾脏中不表达,仅通过逆转录聚合酶链反应在胎儿大脑和胰腺中可检测到。在未经处理的狒狒胎儿中,以18S RNA的比例表示的肝脏CBG的mRNA水平在妊娠早期(1.83±0.17)、中期(0.97±0.12)和晚期(0.51±0.04)逐渐降低(P < 0.05)。这些结果表明,狒狒妊娠早期胎儿肝脏CBG mRNA表达和血清CBG浓度升高,在妊娠进展过程中呈逐渐下降趋势。我们认为,妊娠早期胎儿CBG水平升高反映了母体皮质醇对肝脏CBG合成的刺激,我们之前证明这是由于胎盘优先通过11β - 羟类固醇脱氢酶催化的糖皮质激素还原作用在胎儿中发生的。胎儿CBG的下降可能反映了胎儿靶组织如肝脏中皮质醇向生物活性较低的可的松分解代谢的发育性增加。